悪性中皮腫の世界市場レポート 2025年

悪性中皮腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.7％で34億1,000万米ドルに成長します。予測期間中の成長は、免疫療法治療の採用拡大、個別化医療の重視、低侵襲手術手技の使用増加、ヘルスケア支出の増加、臨床検査数の増加に起因すると考えられます。この期間に予想される主要動向には、免疫療法の進歩、個別化医療、早期発見への取り組み、低侵襲手術、新規制の承認などがあります。

臨床研究開発（R&D）への取り組みの重点化は、今後数年間の悪性中皮腫市場の拡大に大きく寄与すると予想されます。臨床研究開発には、新薬や治療法、医療機器の開発を目的とした科学的研究や検査の実施が含まれます。こうした取り組みでは、管理された臨床検査を通じて新製品の安全性、有効性、潜在的な副作用が評価されます。慢性疾患や複雑な病態の増加により、革新的な治療に対する需要が高まっていることが、こうした研究開発への取り組みを後押ししています。このような取り組みは、診断、治療、悪性中皮腫の標的療法を進歩させ、早期発見を改善し、生存率を高め、より効果的で侵襲の少ない治療法を生み出す新たなアプローチを育成する上で極めて重要です。例えば、Anadolu Agencyの2025年1月のレポートによると、臨床検査は米国の製薬研究予算の40％近くを占め、年間約70億米ドルにのぼります。その結果、研究開発への投資の拡大が悪性中皮腫市場の成長を加速させています。

悪性中皮腫市場の企業は、腫瘍の成長を抑制し、治療の精度を高めるために、モノクローナル抗体のような最先端の治療法の開発に注力しています。モノクローナル抗体は、がん細胞上に存在する抗原を含む特定の抗原を検出し、標的とする免疫系の能力を模倣した実験室製のタンパク質です。例えば、2023年11月、日本の製薬会社である小野薬品工業は、ヒト型抗ヒトPD-1モノクローナル抗体であるオプジーボ（一般名はニボルマブ）について、悪性中皮腫（悪性胸膜中皮腫を除く）に対する効能・効果の追加承認を2023年11月に取得しました。この承認により、オプジーボは、これまで標準治療が確立されていない疾患に対する新たな治療選択肢として導入されました。オプジーボがこの適応症で希少疾病用医薬品に指定されたことは、緊急の医療ニーズに応える可能性を強調するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の悪性中皮腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の悪性中皮腫市場：成長率分析
• 世界の悪性中皮腫市場の実績：規模と成長、2019～2024年
• 世界の悪性中皮腫市場の予測：規模と成長、2024～2029年、2034年
• 世界の悪性中皮腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の悪性中皮腫市場治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 化学療法
• 放射線治療
• 手術
• 免疫療法
• 標的療法
• 世界の悪性中皮腫市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 静脈内
• 注射剤
• 局所
• 世界の悪性中皮腫市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 専門薬局
• 世界の悪性中皮腫市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 腫瘍学クリニック
• リハビリテーションセンター
• ラボ
• 世界の悪性中皮腫市場、化学療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アルキル化剤
• 代謝拮抗剤
• 併用療法
• 世界の悪性中皮腫市場、放射線治療のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 外部放射線治療（EBRT）
• 強度変調放射線治療（IMRT）
• 定位放射線治療（SBRT）
• 陽子線治療
• 世界の悪性中皮腫市場、手術のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 胸膜切除術または胸膜剥離術（P/D）
• 胸膜外肺切除術（EPP）
• 細胞減量手術
• 緩和手術
• 世界の悪性中皮腫市場、免疫療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫チェックポイント阻害剤
• モノクローナル抗体
• 腫瘍ワクチン
• 養子細胞療法
• 世界の悪性中皮腫市場、標的療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• チロシンキナーゼ阻害剤（TKI）
• 血管新生阻害剤
• メソテリン標的薬
• 遺伝子治療によるアプローチ

第7章 地域別・国別分析

• 世界の悪性中皮腫市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の悪性中皮腫市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 悪性中皮腫市場：競合情勢
• 悪性中皮腫市場：企業プロファイル
  • AstraZeneca
  • NYU Langone Health
  • Mayo Foundation for Medical Education and Research
  • The University of Chicago Medical Center
  • Ono Pharmaceutical Co., Ltd.

第31章 その他の大手企業と革新的企業

• Dana-Farber Cancer Institute
• UVA Health
• PharmaMar
• Healthcare Global Enterprises Ltd.
• Fujirebio Europe
• Cancer Healer Center
• Rosetta Genomics
• Mesothelioma UK
• The Mesothelioma Center
• Oncoplus
• Mesothelioma Research Foundation of America
• Pleural Mesothelioma Center

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 悪性中皮腫市場、2029年：新たな機会を提供する国
• 悪性中皮腫市場、2029年：新たな機会を提供するセグメント
• 悪性中皮腫市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Malignant mesothelioma is a rare and aggressive cancer that mainly affects the mesothelium, a thin tissue layer surrounding most of the internal organs. This cancer typically arises in the lung lining (pleura), but it can also develop in the abdomen (peritoneum), heart (pericardium), or testicles. The primary risk factor for malignant mesothelioma is asbestos exposure, a mineral once extensively used in construction and manufacturing.

Treatment options for malignant mesothelioma include chemotherapy, radiation therapy, surgery, immunotherapy, and targeted therapy. Chemotherapy utilizes drugs to destroy cancer cells, slow down tumor growth, and alleviate symptoms. It is commonly administered when the cancer has spread beyond the point where surgery alone would be effective. These drugs can be given through various methods, including oral, intravenous, injectable, and topical. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, which are used by hospitals, oncology clinics, rehabilitation centers, and research laboratories.

The malignant mesothelioma market research report is one of a series of new reports from The Business Research Company that provides malignant mesothelioma market statistics, including malignant mesothelioma industry global market size, regional shares, competitors with a malignant mesothelioma market share, detailed malignant mesothelioma market segments, market trends and opportunities, and any further data you may need to thrive in the malignant mesothelioma industry. This malignant mesothelioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The malignant mesothelioma market size has grown strongly in recent years. It will grow from $2.46 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historical period can be credited to increased investments in oncology research, a rise in asbestos-related litigation cases, higher hospital investments, the aging population, and the expansion of AI-driven drug discovery platforms.

The malignant mesothelioma market size is expected to see strong growth in the next few years. It will grow to $3.41 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth during the forecast period can be attributed to the growing adoption of immunotherapy treatments, a stronger emphasis on personalized medicine, increased use of minimally invasive surgical techniques, higher healthcare spending, and a greater number of clinical trials. Key trends expected during this period include advancements in immunotherapy, personalized medicine, early detection efforts, minimally invasive surgery, and the approval of new regulations.

The growing focus on clinical research and development (R&D) efforts is expected to significantly contribute to the expansion of the malignant mesothelioma market in the coming years. Clinical R&D involves conducting scientific studies and trials aimed at developing new drugs, treatments, and medical devices. These efforts assess the safety, efficacy, and potential side effects of new products through controlled clinical trials. The rising demand for innovative treatments, driven by the increasing prevalence of chronic diseases and complex conditions, is propelling these R&D initiatives. Such efforts are crucial in advancing diagnostics, treatments, and targeted therapies for malignant mesothelioma, fostering new approaches to improve early detection, enhance survival rates, and create more effective, less invasive treatment options. For instance, according to a January 2025 report by Anadolu Agency, clinical trials account for nearly 40% of the U.S. pharmaceutical research budget, amounting to about $7 billion annually. As a result, the growing investment in R&D is accelerating the growth of the malignant mesothelioma market.

Companies in the malignant mesothelioma market are concentrating on developing cutting-edge treatments, such as monoclonal antibodies, to inhibit tumor growth and enhance treatment precision. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to detect and target specific antigens, including those found on cancer cells. For example, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody, for treating malignant mesothelioma (excluding malignant pleural mesothelioma). This approval introduced Opdivo as a new treatment option for a condition with no previously established standard treatments. The designation of Opdivo as an orphan drug for this indication highlights its potential to meet an urgent medical need.

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies for $1.2 billion. This acquisition includes all of Gracell's fully diluted share capital, including the shares represented by American depositary shares. Gracell Biotechnologies, a China-based company, specializes in developing innovative cell therapies for cancer and autoimmune diseases, including malignant mesothelioma.

Major players in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center.

North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in malignant mesothelioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the malignant mesothelioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The malignant mesothelioma market consists of revenues earned by entities by providing services such as genetic testing and biomarker analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant mesothelioma market includes sales of radiation therapy equipment, biopsy kits, diagnostic imaging systems, genetic testing kits, and home healthcare equipment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Malignant Mesothelioma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on malignant mesothelioma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for malignant mesothelioma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The malignant mesothelioma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Radiation Therapy; Surgery; Immunotherapy; Targeted Therapy
• 2) By Route Of Administration: Oral; Intravenous; Injectable; Topical
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
• 4) By End-User: Hospitals; Oncology Clinics; Rehabilitation Centres; Research Laboratories
• Subsegments:
• 1) By Chemotherapy: Alkylating Agents; Antimetabolites; Combination Therapy
• 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy
• 3) By Surgery: Pleurectomy Or Decortication (P/D); Extrapleural Pneumonectomy (EPP); Cytoreductive Surgery; Palliative Surgery
• 4) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Tumor Vaccines; Adoptive Cell Therapy
• 5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Angiogenesis Inhibitors; Mesothelin-Targeted Agents; Gene Therapy-Based Approaches
• Companies Mentioned: AstraZeneca; NYU Langone Health; Mayo Foundation for Medical Education and Research; The University of Chicago Medical Center; Ono Pharmaceutical Co., Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Malignant Mesothelioma Market Characteristics

3. Malignant Mesothelioma Market Trends And Strategies

4. Malignant Mesothelioma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Malignant Mesothelioma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Malignant Mesothelioma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Malignant Mesothelioma Market Growth Rate Analysis
• 5.4. Global Malignant Mesothelioma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Malignant Mesothelioma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Malignant Mesothelioma Total Addressable Market (TAM)

6. Malignant Mesothelioma Market Segmentation

• 6.1. Global Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Radiation Therapy
• Surgery
• Immunotherapy
• Targeted Therapy
• 6.2. Global Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Injectable
• Topical
• 6.3. Global Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies
• 6.4. Global Malignant Mesothelioma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Clinics
• Rehabilitation Centres
• Research Laboratories
• 6.5. Global Malignant Mesothelioma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alkylating Agents
• Antimetabolites
• Combination Therapy
• 6.6. Global Malignant Mesothelioma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Intensity-Modulated Radiation Therapy (IMRT)
• Stereotactic Body Radiation Therapy (SBRT)
• Proton Therapy
• 6.7. Global Malignant Mesothelioma Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pleurectomy Or Decortication (P/D)
• Extrapleural Pneumonectomy (EPP)
• Cytoreductive Surgery
• Palliative Surgery
• 6.8. Global Malignant Mesothelioma Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Monoclonal Antibodies
• Tumor Vaccines
• Adoptive Cell Therapy
• 6.9. Global Malignant Mesothelioma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors (TKIs)
• Angiogenesis Inhibitors
• Mesothelin-Targeted Agents
• Gene Therapy-Based Approaches

7. Malignant Mesothelioma Market Regional And Country Analysis

• 7.1. Global Malignant Mesothelioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Malignant Mesothelioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Malignant Mesothelioma Market

• 8.1. Asia-Pacific Malignant Mesothelioma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Malignant Mesothelioma Market

• 9.1. China Malignant Mesothelioma Market Overview
• 9.2. China Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Malignant Mesothelioma Market

• 10.1. India Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Malignant Mesothelioma Market

• 11.1. Japan Malignant Mesothelioma Market Overview
• 11.2. Japan Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Malignant Mesothelioma Market

• 12.1. Australia Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Malignant Mesothelioma Market

• 13.1. Indonesia Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Malignant Mesothelioma Market

• 14.1. South Korea Malignant Mesothelioma Market Overview
• 14.2. South Korea Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Malignant Mesothelioma Market

• 15.1. Western Europe Malignant Mesothelioma Market Overview
• 15.2. Western Europe Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Malignant Mesothelioma Market

• 16.1. UK Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Malignant Mesothelioma Market

• 17.1. Germany Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Malignant Mesothelioma Market

• 18.1. France Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Malignant Mesothelioma Market

• 19.1. Italy Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Malignant Mesothelioma Market

• 20.1. Spain Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Malignant Mesothelioma Market

• 21.1. Eastern Europe Malignant Mesothelioma Market Overview
• 21.2. Eastern Europe Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Malignant Mesothelioma Market

• 22.1. Russia Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Malignant Mesothelioma Market

• 23.1. North America Malignant Mesothelioma Market Overview
• 23.2. North America Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Malignant Mesothelioma Market

• 24.1. USA Malignant Mesothelioma Market Overview
• 24.2. USA Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Malignant Mesothelioma Market

• 25.1. Canada Malignant Mesothelioma Market Overview
• 25.2. Canada Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Malignant Mesothelioma Market

• 26.1. South America Malignant Mesothelioma Market Overview
• 26.2. South America Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Malignant Mesothelioma Market

• 27.1. Brazil Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Malignant Mesothelioma Market

• 28.1. Middle East Malignant Mesothelioma Market Overview
• 28.2. Middle East Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Malignant Mesothelioma Market

• 29.1. Africa Malignant Mesothelioma Market Overview
• 29.2. Africa Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Malignant Mesothelioma Market Competitive Landscape And Company Profiles

• 30.1. Malignant Mesothelioma Market Competitive Landscape
• 30.2. Malignant Mesothelioma Market Company Profiles
  • 30.2.1. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. NYU Langone Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mayo Foundation for Medical Education and Research Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. The University of Chicago Medical Center Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Ono Pharmaceutical Co., Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Malignant Mesothelioma Market Other Major And Innovative Companies

• 31.1. Dana-Farber Cancer Institute
• 31.2. UVA Health
• 31.3. PharmaMar
• 31.4. Healthcare Global Enterprises Ltd.
• 31.5. Fujirebio Europe
• 31.6. Cancer Healer Center
• 31.7. Rosetta Genomics
• 31.8. Mesothelioma UK
• 31.9. The Mesothelioma Center
• 31.10. Oncoplus
• 31.11. Mesothelioma Research Foundation of America
• 31.12. Pleural Mesothelioma Center

32. Global Malignant Mesothelioma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Malignant Mesothelioma Market

34. Recent Developments In The Malignant Mesothelioma Market

35. Malignant Mesothelioma Market High Potential Countries, Segments and Strategies

• 35.1 Malignant Mesothelioma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Malignant Mesothelioma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Malignant Mesothelioma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer